Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Varicella zoster immunoglobulin

Generic name
Varicella zoster immunoglobulin
Brand name
ATC Code
J06BB03

Pharmacokinetics in children

No information

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Problems with availabiliity of the drug
  • Route of administration not applicable
    • 0 years up to 18 years

      • VariQuin will be unavailable for a long time. That is why the Dutch Health and Youth Care Inspectorate has given permission for VariZIG to be imported without the inspectorate’s prior individual authorization.
Prevention of varicella (chicken pox)
  • Intramuscular
    • < 2 kg
      • 125 IU/dose, once only. In the event of further exposure, repeat the dose at least 3 weeks later..
      • Directions for administration:

        Administer slowly, deep intramuscular. The preparation should preferably be brought to body temperature before administering it.

      • There is only any point administering it if the contact with a varicella zoster patient was not more than 72 hours ago.

    • 2 up to 10 kg
      • 250 IU/dose, once only. In the event of further exposure, repeat the dose at least 3 weeks later.
      • Directions for administration:

        Administer slowly, deep intramuscular. The preparation should preferably be brought to body temperature before administering it.

      • Administer as quickly as possible, preferably within 3 days and by no later than 10 days after there was contact with a varicella zoster patient.

    • 10 up to 30 kg
      • 500 IU/dose, once only. In the event of further exposure, repeat the dose at least 3 weeks later..
      • Directions for administration:

        Administer slowly, deep intramuscular. The preparation should preferably be brought to body temperature before administering it.

      • Administer as quickly as possible, preferably within 3 days and by no later than 10 days after there was contact with a varicella zoster patient.

    • ≥ 30 kg
      • 625 IU/dose, once only. In the event of further exposure, repeat the dose at least 3 weeks later..
      • Directions for administration:

        Administer slowly, deep intramuscular. The preparation should preferably be brought to body temperature before administering it.

      • Administer as quickly as possible, preferably within 3 days and by no later than 10 days after there was contact with a varicella zoster patient.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Immunoglobulins, normal human
J06BA02
J06BA01
Specific immunoglobulins
J06BB01
J06BB04
J06BB02
Antibacterial monoclonal antibodies
J06BC03
IMMUNOGLOBULINS, NORMAL HUMAN
J06BA02
J06BA01
Antiviral monoclonal antibodies
J06BD07
J06BD08
J06BD01

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. Rademaker C.M.A. et al, Geneesmiddelen Formularium voor Kinderen, 2007
  2. Sanquin, SPC Variquin (RVG 16948) 25-03-2015, www.geneesmiddeleninformatiebank.nl
  3. CBO, Richtlijn Varicella, www.cbo.nl, 2003, http://www.cbo.nl/Downloads/275/varicella2003.pdf
  4. Aptevo Bio Therapeutics LLC, SmPC VariZIG Licentienr VS 2054, https://www.sanquin.org/nl/producten-en-diensten/plasmageneesmiddelen/producten-en-bijsluiters/immunoglobulinen/variquin
  5. Sanquin, Produktinformatie Varicella Zoster Immunoglobuline , www.sanquin.org, 19-07-2018
  6. Sanquin, Produktinformatie Varicella Zoster Immunoglobuline, www.sanquin.org, 19-07-2018

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes